- Estimates suggest obstructive sleep apnea (“OSA”) costs the US economy $150 billion annually
- Medicare beneficiaries with obstructive sleep apnea cost taxpayers $19,566 per year
- Company’s oral appliances have shown to be effective in over 15,000 patients, successfully treated worldwide by approximately 1,250 trained dentists and doctors
It is estimated that obstructive sleep apnea (“OSA”) affects approximately 1 billion people worldwide, of which 54 million are Americans (http://nnw.fm/jrHQ6). According to a study published by the Journal of Clinical Sleep Medicine, individuals with untreated OSA face increased health care utilization (“HCU”) and costs across all service aspects. Costs and HCU were evaluated by researchers over the period of a year leading up to the initiation of treatment. According to Emerson Wickwire, PhD, a lead author of the study, sleep disorders represent a massive economic burden on the U.S. health care system. Medicare beneficiaries with obstructive sleep apnea cost taxpayers an additional $19,566 per year. They also use more emergency, outpatient, inpatient, prescription health services, and medical services in general (http://nnw.fm/t0d6D).
According to the American Academy of Sleep Medicine, the economic burden of undiagnosed sleep apnea is about $150 billion a year in the U.S. alone, and diagnosing and treating every patient who is suffering from the condition may generate annual savings of $100 billion (http://nnw.fm/obc8C).
Vivos Therapeutics’ proprietary Vivos System(R) has the potential to help reduce these costs significantly, being the first treatment modality for mild to moderate OSA that can potentially do away with the need for lifelong interventions. The system’s typical 18-24 month treatment time is a fraction of that of alternative treatments. Adults often experience immediate relief with potentially lasting benefits in a matter of months, with the possibility of eliminating the need for surgery (http://nnw.fm/7opjM).
The multidisciplinary treatment protocol is comprised of comfortable and customized oral devices along with other therapies as needed. In most patient’s, the upper airway is effectively increased and enhanced over the course of treatment, which typically ranges from 18 to 24 months. The purpose is to reduce tissue obstructions causing OSA. Vivos’ technology represents the first true hope of an effective non-surgical OSA solution (http://nnw.fm/SuE6g).
Vivos Therapeutics, Inc. offers a new and superior alternative for treating obstructive sleep apnea and the company believes its technology represents the most important breakthrough in OSA treatment since CPAP (Continuous Positive Airway Pressure), which involves the use of special face or nasal masks.
Almost all commercial health insurance carriers offer reimbursement for the Vivos System and products. Individual policies and reimbursement options will vary based on an individual’s policy. These unique oral devices are non-invasive and yet, unlike other OSA approaches, treat the underlying condition. Vivos is expanding its technology applications and is now running WIRB approved clinical trials to evaluate oral appliance therapy in pediatrics as the FDA does not currently recognize the treatment sleep disorder breathing for pediatrics with oral appliance therapy. The Vivos System treats the underlying condition for people of all ages.
Vivos Therapeutics is an emerging global leader in the treatment of OSA. Headquartered in Denver, Colorado, the company utilizes proprietary, groundbreaking technology; a proven, go-to-market strategy; and a powerful executive team dedicated to changing the face of health care by helping people of all ages breathe and sleep properly.
Trained dentists use the Vivos System to treat the conditions associated with SDB and OSA. The company is rapidly expanding the use of the Vivos System by involving dentists earlier and more actively in the process of diagnosing and treating OSA. In support of its growth strategy, Vivos has established FDA-approved and registered manufacturing facilities in the United States, Canada and Asia. The company’s oral appliances have shown to be effective in over 15,000 patients successfully treated worldwide by approximately 1,250 trained dentists.
For more information, visit the company’s website at www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://nnw.fm/VVOS
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork.
